Healthcare / Drug Manufacturers - Specialty & GenericBSE
$207.05
-3.40 (-1.62%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-1.7B · quality 33.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$19.1B
P/E
N/A
•EV/EBITDA
20.9x
↑ROE
-10.1%
↓Gross Margin
69.8%
↑Debt/Equity
1.16
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+3.0%
FCF CAGR
—
FCF margin
5.6%
FCF / Net income
-1.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $17.93B · net income $-951.5M · FCF $1.01B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $17.93B | $17.93B | $16.41B | $17.88B | $16.40B |
| Net Income | $-951.5M | $-951.5M | $-737.4M | $984.6M | $1.42B |
| EBITDA | $1.42B | $1.42B | $1.06B | $2.63B | $2.87B |
| EPS | — | — | -8.46 | 10.67 | 15.42 |
| Gross Margin | 69.8% | 69.8% | 69.6% | 67.4% | 67.1% |
| Operating Margin | 0.9% | 0.9% | -0.9% | 8.0% | 12.1% |
| Net Margin | -5.3% | -5.3% | -4.5% | 5.5% | 8.7% |
| Balance Sheet | |||||
| Debt/Equity | 1.16 | 1.16 | 0.97 | 0.61 | 0.32 |
| Cash Flow | |||||
| Free Cash Flow | $1.01B | $1.01B | $-1.68B | $-2.71B | $-284.2M |
| Returns | |||||
| ROE | -10.1% | -10.1% | -7.2% | 8.9% | 13.8% |
| Valuation | |||||
| P/E | — | — | — | 32.69 | 21.37 |
| EV/EBITDA | 20.90 | 20.90 | 29.73 | 14.76 | 11.70 |
| P/B | 2.03 | 2.03 | 2.11 | 2.90 | 2.95 |
| Growth & Yield | |||||
| Revenue Growth | 9.2% | 9.2% | -8.2% | 9.0% | — |
| EPS Growth | — | — | -179.3% | -30.8% | — |
| Dividend Yield | 0.1% | 0.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-8.46 → n/d
Residual
-14.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.